Biotechnology company developing a novel platform technology designed to overcome antibacterial resistance
At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.
Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPject™ could form the basis for a new generation of antibiotics to overcome antimicrobial resistance.
Visit website: http://www.phicotx.co.uk/